[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastases":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,51,73,99,129,160,191,218,238,266,289,309],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100606496","phase-2-zanidatamab-in-combination-with-pembrolizumab-and-chemotherapy-in-her2-and-pd-l1-positive-metastatic-gastroesophageal-adenocarcinoma-gea-patients-100606496",false,"NCT07176312","Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","- ZANGEA - Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients","ZANGEA","Inclusion Criteria:\n\n* Patient\\* has signed and dated a written informed consent form in accordance with regulatory and institutional guidelines and approved by an institutional Review Board \u002F Independent Ethics Committee. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.\n* Patient is, in the investigator's judgement, willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.\n* Patient is ≥ 18 years of age at time of signing the written informed consent.\n* Patient has been diagnosed with histologically confirmed unresectable advanced\u002Fmetastatic HER2-positive (defined as IHC 3+ or IHC 2+ with ISH+) and PD-L1-positive (combined positive score CPS ≥ 1) gastroesophageal adenocarcinoma per local standard assessment of new or archival tumor tissue. Results of local HER2 and PD-L1 assessment will be retrospectively confirmed by central pathological re-assessment.\n\nNote: In case of metachronous metastases, particularly in case of prior treatment with PD-(L)1-antibodies, a fresh re-biopsy should be performed for immunohistochemistry testing (local pathology), if feasible.\n\n* Patient has assessable disease (measurable or non-measurable) per RECIST v1.1.\n* Patient did not receive previous palliative treatment. Prior adjuvant or neoadjuvant chemotherapy, immunotherapy, radiotherapy and\u002For chemoradiotherapy (but not anti HER2-targeted treatment) are permitted as long as the last administration of the last regimen (whichever was given last) occurred at least 6 months prior to enrolment.\n* Patient has ECOG performance status ≤ 1.\n* Patient has adequate hepatic, renal and hematologic functions:\n\n  1. Absolute number of neutrophils (ANC) ≥ 1.5 x 10\\^9\u002FL\n  2. Platelets ≥ 100x10\\^3\u002FµL\n  3. Serum creatinine ≤ 1.5 x ULN or creatinine clearance (measured by 24 h urine) ≥ 30 mL\u002Fmin (i.e., if serum creatinine level is \\> 1.5 x upper limit of normal (ULN), then a 24-hour urine test must be performed to check the creatinine clearance to be determined.\n  4. AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN (or ≤ 5.0 x ULN if liver metastases are present)\n  5. Total Bilirubin ≤ 1.5 x ULN (or \\\u003C 3.0 x ULN in case of prior liver involvement or Gilbert's Syndrome)\n* Patient has adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy).\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotrophin \\[hCG\\]) within 7 days prior to the start of study drug. Women must not be breastfeeding. WOCBP must use a highly effective method(s) of contraception during the treatment period and for 4 months after last dose of zanidatamab and\u002For pembrolizumab, or 6 months after the last dose of chemotherapy, whichever occurs last. Males who are sexually active with WOCBP must agree to remain abstinent or follow instructions for method(s) of contraception during the treatment and for 4 months after the last dose of zanidatamab and\u002For pembrolizumab, or 6 months after the last dose of chemotherapy, whichever occurs last. In addition, male subjects must be willing to refrain from sperm donation during this time.\n\n  * There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently.\n\nExclusion Criteria:\n\n* Patient has any known contraindication including allergy or hypersensitivity to the trial drugs or any constituent of the products as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies.\n* Patient received prior anti HER2-targeted treatment for GEA.\n* Patient has malignancies other than the disease under study within 5 years prior to inclusion, except for those with a negligible risk of metastasis or death (e.g., expected 5-year OS \\> 90%) treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent).\n* Patient has untreated known CNS metastases. Patient is eligible, if previous CNS metastases are adequately treated and patient has neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for ≥ 2 weeks prior to enrolment, and did not receive corticosteroids, or is on a stable or decreasing dose of \\\u003C 10 mg daily prednisone (or equivalent) for ≥ 2 weeks prior to inclusion.\n* Patient has abnormal baseline left ventricular ejection fraction (LVEF \\\u003C 50 %), assessed by echocardiogram, multigated acquisition (MUGA) scan, or cardiac magnetic resonance imaging (MRI) scan.\n* Patient has active, known, or suspected autoimmune disease. Exception: Type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll. For any cases of uncertainty, it is recommended that the medical expert\u002Fsponsor be consulted prior to signing informed consent.\n* Patient has a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of trial drug administration. Inhaled or topical steroids, and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n* Patient has persisting toxicity related to prior therapy (NCI CTCAE v.5.0 Grade \\> 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.\n* Patient has any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with trial participation, trial drug administration, or would impair the ability of the patient to receive trial drug.\n* Patient has significant acute or chronic infections including, among others:\n* Any positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n* Any positive test result for hepatitis B virus or hepatitis C virus indicating acute or chronic infection.\n* Patient has history of allogeneic tissue \u002F solid organ transplant.\n* Patient has been incarcerated or involuntarily institutionalized by court order or by the authorities \\[§ 40 Abs. 1 S. 3 Nr. 4 AMG\\].\n* Patient is unable to consent because he\u002Fshe does not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts \\[§ 40 Abs. 1 S. 3 Nr. 3a AMG\\].\n* Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the trial medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of trial results.\n* Patient currently participates in any other interventional clinical study within 30 days before the first administration of the investigational product or at any time during the trial, unless it is an observational (non-interventional) study, or during the follow-up period of an interventional study with last dose of investigational product ≥28 days prior to enrolment in this trial.\n* Patient has a known complete absence of dihydropyrimidine dehydrogenase (DPD) activity or use of any medications known to inhibit DPD (including brivudine, sorivudine and analogs) within 4 weeks prior to enrolment.\n* Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of trial treatment.","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA). The patients need to be previously untreated in the palliative setting and tested positive for HER2 and PD-L1.",[27,28,29,30,31],"Gastroesophageal Adenocarcinoma","First Line Therapy","HER2 + Gastric Cancer","PDL-1","Metastases",[33,34,35,36,37],"GEA","Gastroesophageal adenocarcinoma","first line therapy","HER2-positive","PD-L1 positive","RECRUITING","2026-06-29",{"date":41,"type":42},"2026-06-30","ACTUAL",{"date":44,"type":42},"2026-01-16",{"date":46,"type":21},"2029-03",{"name":48,"class":49},"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","OTHER",20,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100454297","phase-1-preoperative-y-90-radioembolization-for-tumor-control-and-future-liver-remnant-hypertrophy-in-patients-with-colorectal-liver-metastases-100454297","NCT05195710","Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases","Inclusion Criteria:\n\n* Borderline resectable unresectable (due to insufficient liver volume at presentation) colorectal liver metastases with potential curative intent, as determined by the surgeon and multidisciplinary team\n* Anticipated standardized FLR (sFLR) that would require right portal vein embolization (PVE) to increase the sFLR prior to either a single major hepatectomy, or prior to the second stage hepatectomy as part of a two-stage hepatectomy strategy, all in the setting of curative-intent resection(s). This evaluation will be documented in the clinical chart\n* Received at least four cycles (or two months) of chemotherapy\n* Willing, able and mentally competent to provide written informed consent\n* Medically and physically operable as determined by the surgeon\n\nExclusion Criteria:\n\n* Extrahepatic disease that precludes intended curative intent treatment sequencing (treatable primary tumor and lung metastases allowed). \"Treatable\" is defined as having an intended future plan for local therapy (surgery, radiation, or ablation) as determined by the patient's medical oncologist and surgical oncologist\n* Projected sFLR before Y-90 of \\\u003C20% (starting with sFLR that is unrealistic for improvement to ≥30%)\n* Performance status limitations (Karnofsky \\\u003C80%, ECOG \\>1)\n* Portal hypertension and\u002For cirrhosis\n* Starting total bilirubin \\>1.3 mg\u002FdL (except if patient has Gilbert's Disease)\n* CEA \\>200 after 4 cycles of chemotherapy upon restaging visit\n* Clinical progression of disease on imaging and\u002For tumor marker after 4 cycles of chemotherapy that is clinically judged by surgical oncology and medical oncology to preclude surgical resection\n* Platelet count \\\u003C100,000\u002FµL\n* Albumin \\\u003C3.5 g\u002Fdl\n* Symptomatic primary colon or rectal cancer (without pre-existing proximal diverting ostomy)\n* Pregnant or breast-feeding patient\n* Other medical or clinical contraindications to liver surgery\n* Non-English-speaking participants",{"count":58,"type":21},50,[60],"PHASE1","A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.",[31],"2026-05-22",{"date":65,"type":42},"2026-05-26",{"date":67,"type":42},"2022-11-16",{"date":69,"type":21},"2028-03-31",{"name":71,"class":49},"M.D. Anderson Cancer Center",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":72},"100638693","phase-2-trial-comparing-lattice-radiotherapy-vs-moderately-dose-escalated-palliative-radiation-for-patients-with-metastases-100638693","NCT07594431","Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.","A Randomized Phase II Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.","80 patients with confirmed metastatic tumor (\\>2.5 cm in short axis) will be enrolled, all ≥ 12 years of age with ECOG ≤ 2. All genders and races will be included.\n\nInclusion Criteria:\n\n* Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer\n* One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: \\>2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is \\>2.5 cm in short axis\n* Age ≥12\n* ECOG Performance Status 0-2\n* For patients age 12-16, Lansky Play-Performance score 50-100\n* Negative serum or urine pregnancy test within 2 weeks prior to enrollment of people of childbearing potential\n* All patients and\u002For their parents or legal guardians must sign a written informed consent. For any child less than 18 years of age, assent must also be obtained in addition to parental or legal guardian consent.\n\nExclusion criteria:\n\n* Prior radiation therapy to the tumor to be treated\n* Active pregnancy\n* Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome\n* The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma","12 Years",{"count":20,"type":21},[24],"Unblinded, randomized study of 5-fraction LATTICE radiotherapy (20 Gy with an SIB to 66.7 Gy in 5 fractions) versus moderately dose-escalated palliative radiation (25 Gy in 5 fractions)",[31,85],"Metastatic Cancer",[87,88],"LATTICE Radiotherapy","Palliative Radiotherapy","NOT_YET_RECRUITING","2026-05-12",{"date":92,"type":42},"2026-05-18",{"date":94,"type":21},"2026-08",{"date":96,"type":21},"2028-08",{"name":98,"class":49},"Stanford University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":4},"100637874","phase-1-safety-tolerability-and-preliminary-antitumor-activity-of-non-cationic-peptide-cd47-sirna-in-advanced-solid-tumors-100637874","NCT07583914","Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors","A Clinical Trial of Non-cationic Peptide-CD47 siRNA for Safety, Tolerability, and Preliminary Antitumor Activity in Patients With Advanced Malignant Solid Tumors","Inclusion Criteria:\n\n* Male or female patients aged ≥18 years and ≤70 years.\n* Histopathologically confirmed advanced recurrent\u002Fmetastatic malignant solid tumors that are refractory to second-line treatment and have no available standard clinical therapeutic options (e.g., advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, malignant melanoma, etc.).\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n* Expected overall survival ≥3 months.\n* Interval from the last chemotherapy, radiotherapy, or surgery ≥28 days.\n* Interval from the last use of nitrosourea or mitomycin C ≥6 weeks.\n* Adequate organ function, defined by the following laboratory parameters within 14 days prior to enrollment:\n* Hemoglobin ≥90 g\u002FL (no blood transfusion within 14 days).\n* Absolute neutrophil count \\>1.5 × 10⁹\u002FL.\n* Platelet count ≥80 × 10⁹\u002FL.\n* Total bilirubin ≤1.5 × upper limit of normal (ULN).\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5 × ULN (≤5 × ULN in case of liver metastasis).\n* Creatinine clearance ≥60 mL\u002Fmin (calculated by Cockcroft-Gault formula).\n* Left ventricular ejection fraction (LVEF) ≥50%.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Participation in another investigational drug clinical trial within 4 weeks.\n* Tumor located adjacent to major blood vessels or trachea.\n* Uncontrolled cardiac clinical symptoms or diseases, including New York Heart -Association (NYHA) Class ≥2 heart failure, unstable angina, myocardial infarction within 1 year, or clinically significant supraventricular\u002Fventricular arrhythmias requiring treatment or intervention.\n* Female patients who are pregnant or lactating.\n* Active pulmonary tuberculosis, bacterial or fungal infection (≥Grade 2 per NCI-CTCAE version 5.0), active human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection.\n* History of uncontrollable psychoactive substance abuse or presence of mental disorders.\n* Any active autoimmune disease or history of autoimmune disease, including but not limited to uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism, and hypothyroidism. Subjects with vitiligo or childhood asthma in complete remission (no adult intervention required) are eligible; subjects with asthma requiring bronchodilator therapy are excluded.\n* Receiving immunosuppressive therapy.\n* History of drug abuse or known medical, psychological, or social conditions that interfere with study compliance (e.g., alcoholism or illicit drug addiction).\n* Known hypersensitivity, allergy, or intolerance to the study drug NCP-CD47 siRNA (including any excipients), or history of severe allergic reactions to any drugs, foods, or vaccines (e.g., anaphylactic shock, allergic laryngeal edema, allergic dyspnea, allergic purpura, thrombocytopenic purpura, local Arthus reaction, etc.).\n* Female subjects planning pregnancy, or male subjects whose partner plans pregnancy, from screening until 12 months after the last study drug injection.\n* Any concomitant disease that, in the investigator's judgment, may seriously compromise patient safety or prevent the subject from completing the study.","70 Years",{"count":108,"type":21},9,[60],"This study evaluates a non-cationic peptide-CD47 siRNA nanocomplex for refractory advanced solid tumors. The candidate blocks the CD47-SIRPα \"don't eat me\" signal, repolarizes tumor-associated macrophages, and restores antitumor immunity. Using a 3+3 dose-escalation design (25, 50, 100 μg), the investigators aim to define the MTD and RP2D, providing a novel therapeutic approach and clinical evidence for siRNA drug development.",[112,31,113],"Solid Tumor Cancer","Head and Neck Cancer",[115,116,117,118,119],"Solid Tumor","siRNA","Cancer metastasis","Progress-free survival","Overall survival","2026-05-06",{"date":122,"type":42},"2026-05-13",{"date":124,"type":21},"2026-05-30",{"date":126,"type":21},"2027-12-30",{"name":128,"class":49},"West China Hospital",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":156,"leadSponsor":158,"locationsCount":72},"100634304","phase-3-local-consolidation-after-sintilimab-plus-lenvatinib-for-metastatic-liver-cancer-100634304","NCT07537946","Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer","Comprehensive Local Consolidative Therapy Versus Continued Sintilimab Plus Lenvatinib Alone After Induction Sintilimab Plus Lenvatinib in Patients With Oligo-Extrahepatic Metastatic Hepatocellular Carcinoma: A Multicenter Prospective Randomized Trial","Inclusion Criteria:\n\n* Age 18 to 75 years\n* Hepatocellular carcinoma confirmed by imaging and\u002For histology according to institutional diagnostic standards\n* Advanced or unresectable disease with extrahepatic metastases meeting protocol-defined oligo-extrahepatic metastatic disease criteria: 1 to 5 extrahepatic metastatic lesions and no more than 2 involved extrahepatic organs\n* At least 1 measurable lesion according to RECIST version 1.1\n* No prior systemic therapy for advanced or metastatic hepatocellular carcinoma\n* ECOG performance status 0 to 1\n* Child-Pugh class A or stable Child-Pugh B7\n* Adequate hematologic, hepatic, renal, and coagulation function according to protocol\n* Baseline center multidisciplinary team assessment indicating potential feasibility for complete consolidative intent if disease control is achieved after induction\n* Written informed consent and willingness to comply with treatment, follow-up, and protocol-required assessments\n\nExclusion Criteria:\n\n* More than 5 extrahepatic metastatic lesions or more than 2 involved extrahepatic organs\n* Diffuse peritoneal seeding, leptomeningeal disease, or uncontrolled brain metastases\n* Main portal vein trunk invasion, extensive inferior vena cava or right atrial tumor thrombus, or disease considered unlikely to become fully consolidable after induction\n* Diffuse intrahepatic disease or liver tumor burden considered unlikely to be controllable with protocol-specified local treatment\n* Prior PD-1, PD-L1, CTLA-4, anti-VEGF monoclonal antibody, tyrosine kinase inhibitor, or other systemic antitumor therapy for advanced HCC\n* Active autoimmune disease requiring systemic immunosuppression\n* Active severe infection, including uncontrolled bacterial or fungal infection, active tuberculosis, or uncontrolled hepatitis B without appropriate antiviral therapy\n* Gastrointestinal bleeding within the previous 6 months, or untreated or uncontrolled high-risk gastroesophageal varices\n* Uncontrolled hypertension, recent major thrombotic event, myocardial infarction, unstable angina, or stroke\n* Active interstitial lung disease or noninfectious pneumonitis requiring systemic treatment\n* Severe proteinuria or renal dysfunction considered unsuitable for lenvatinib treatment\n* Pregnancy or breastfeeding\n* Any condition that, in the investigator's judgment, would make participation unsafe or compromise protocol compliance","75 Years",{"count":138,"type":21},400,[140],"PHASE3","This study evaluates whether comprehensive local consolidative therapy added to continued sintilimab plus lenvatinib improves survival compared with continued sintilimab plus lenvatinib alone in patients with oligo-extrahepatic metastatic hepatocellular carcinoma. All enrolled participants receive induction treatment with sintilimab plus lenvatinib for 4 cycles. Participants who achieve disease control and are confirmed by central multidisciplinary review to be feasible for complete consolidation are randomized in a 1:1 ratio to receive either comprehensive local consolidative therapy followed by continued systemic therapy or continued systemic therapy alone. The primary outcome is overall survival.",[143,31],"Hepatocellular Carcinoma (HCC)",[145,146,147,148,149,150,151],"Oligometastatic","Hepatocellular Carcinoma","Sintilimab","Lenvatinib","Comprehensive Local Consolidative Therapy","Surgery","Ablation","2026-04-12",{"date":154,"type":42},"2026-04-17",{"date":124,"type":21},{"date":157,"type":21},"2031-07-30",{"name":159,"class":49},"Tongji Hospital",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":168,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":72},"100633064","exercise-training-in-women-with-metastatic-breast-cancer-100633064","NCT07521826","Exercise Training in Women With Metastatic Breast Cancer","Randomized Controlled Trial of a Combined Exercise Training Program on Physical Function and Quality of Life in Women With Metastatic Breast Cancer","FITCAN","Inclusion Criteria:\n\n* Women aged ≥ 18 years;\n* Confirmed diagnosis of stage IV (metastatic) breast cancer;\n* Currently undergoing medical treatment;\n* Willingness and functional independence to participate in the exercise program;\n* Medical clearance to engage in structured physical exercise.\n\nExclusion Criteria:\n\n* Presence of unstable bone metastases.\n* Untreated or symptomatic brain metastases;\n* Evidence of severe cardiovascular disease identified by electrocardiogram (ECG);\n* Severe active infection;\n* Uncontrolled severe respiratory insufficiency or dependence on supplemental oxygen at rest or during exercise;\n* Uncontrolled severe pain;\n* Any other medical condition contraindicating participation in physical exercise;\n* Conditions that impair adherence to study procedures or the ability to provide informed consent;\n* Pregnancy.","FEMALE",{"count":170,"type":21},78,[172],"NA","The primary objective of the study is to evaluate the effects of exercise on physical function, physical fitness, and body composition, with the main components including muscular strength, cardiorespiratory fitness, muscle mass, fat mass, and fat-free mass. The secondary objectives are to examine exercise adherence and the effects of exercise on health-related quality of life (HRQoL), cancer-related fatigue, and sleep quality. Additionally, the feasibility and safety of the exercise program will be assessed.",[175,31],"Cancer",[177,178,179,180,181],"Low muscle strength","muscle loss","loss of physical function","cardiorespiratory fitness","multimodal exercise","2026-04-07",{"date":184,"type":42},"2026-04-13",{"date":186,"type":21},"2026-04",{"date":188,"type":21},"2028-12",{"name":190,"class":49},"State University of Londrina",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":108},"100438269","68ga-psma-pet-in-the-renal-cell-carcinoma-100438269","NCT04987086","68Ga-PSMA PET in the Renal Cell Carcinoma","A Prospective, Multicenter Study of Diagnostic Efficiency of 68Ga-PSMA PET in the Patients With Locally Advanced and Advanced Renal Cell Carcinoma","Inclusion Criteria:\n\n* 2017 AJCC renal cell carcinoma TNM stage III, IV lesions;\n* In contrast-enhanced CT staging, suspicious metastases were found;\n* There were no known peripheral or central venous problems;\n* 68Ga PSMA PET \u002F CT imaging can be performed within 6 weeks after the diagnosis of renal cell carcinoma;\n* Signed the informed consent form of voluntary participation in clinical trials.\n\nExclusion Criteria:\n\n* Age ≤ 18 years old;\n* Can't stand lying flat in PET \u002F CT examination;\n* There are contraindications for 68Ga PSMA ligands;\n* In the past two years, there was a history of other malignant tumors, or according to the doctor's research judgment, complications may occur and affect the normal operation of the test;\n* Renal function is impaired or hemodialysis is in progress.","90 Years",{"count":200,"type":21},300,[172],"The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma",[204,31,205],"Renal Cancer","PSMA PET",[207,205,208],"advnaced renal cancer","metastases","2026-03-08",{"date":211,"type":42},"2026-03-11",{"date":213,"type":42},"2021-06-01",{"date":215,"type":21},"2027-12-01",{"name":217,"class":49},"Xijing Hospital",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":72},"100615383","high-dose-radiotherapy-for-palliation-hi-d-100615383","NCT07291895","High Dose Radiotherapy for Palliation (Hi-D)","A Prospective Single-blinded Randomized Study of High Dose Radiotherapy for Palliation: Hi-D","Inclusion Criteria:\n\n* Subjects must meet all the following criteria to be eligible for participation in this study:\n* Age 18 or older.\n* Able to provide informed consent\n* Patient has histologically confirmed solid tumour malignancy\n* ECOG performance status 0 - 2\n* Life Expectancy \\> 6 months\n* 1-5 target lesions larger than 5cm\n* A history and physical exam, including ECOG performance status, performed within 6 weeks prior to trial enrollment\n* Not suitable for or declined curative-intent treatment\n* Subject has had a CT neck, chest, abdomen and pelvis or PET-CT within 8 weeks prior to enrollment, and with 12 weeks of treatment\n* MRI spine for patients receiving RT to vertebral or paraspinal metastases\n* Patient is judged able to:\n\n  * Maintain a stable position during therapy\n  * Tolerate immobilization device(s) that may be required to deliver radiation safely\n\nExclusion Criteria:\n\n* \\- Hematologic malignancy.\n* Disease limited to intracranial sites\n* Serious medical co-morbidities precluding radiotherapy\n* Bone metastases with no soft tissue component\n* Prior radiation to target lesion that precludes delivery of repeat radiation. All such cases should be discussed with the local and study PIs.\n* Pregnant women",{"count":50,"type":21},[172],"The goal of this clinical trial is to evaluate the feasibility of single-blind randomization between two palliative regimens - standard 24 Gray in 3 fractions vs a high-dose (Hi-D) 27 Gray in 3 fractions with dose escalation within the tumor in participants with bulky metastatic cancer.\n\nThe main question",[31,88],"2025-12-05",{"date":231,"type":42},"2025-12-18",{"date":233,"type":21},"2026-01-01",{"date":235,"type":21},"2029-08-31",{"name":237,"class":49},"British Columbia Cancer Agency",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":168,"minAge":18,"maxAge":136,"enrollmentInfo":244,"targetDuration":4,"studyType":246,"phases":4,"briefSummary":247,"conditions":248,"keywords":252,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":72},"100594366","epcam-targeted-surface-enhanced-raman-spectroscopy-nanotags-for-rapid-evaluation-of-surgical-margins-and-sentinel-lymph-node-metastasis-status-in-breast-cancers-100594366","NCT07018505","EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph Node Metastasis Status in Breast Cancers","Inclusion Criteria:\n\n* Adult patients between 18-75 years of age\n* Female\n* Patients presenting with a breast cancer to be resectable on pre-operative assessment\n* Good operative candidate\n* Subject capable of giving informed consent and participating in the process of consent\n\nExclusion Criteria:\n\n* Patients unable to participate in the consent process\n* Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc\n* Other conditions that the researcher considers inappropriate to participate in the study",{"count":245,"type":21},40,"OBSERVATIONAL","For early breast cancer patients, breast-conserving surgery and sentinel lymph node biopsy have emerged as the cornerstone of precision oncology, harmonizing oncologic efficacy with the preservation of breast cosmetics and axillary function. However, conventional margin evaluation relies on subjective experience, leading to positive margin rates of 15%-50% Additionally, sentinel lymph node biopsy faces inherent technical limitations, including prolonged procedural time and significant false-negative rates in detecting micro-metastases. To overcome these challenges, the investigators will introduce a stable \"sandwich\" EpCAM-targeted surface-enhanced Raman spectroscopy (SERS) detection system to provide rapid evaluation of surgical margins and sentinel lymph node (SLN) metastasis status. In brief, a portion of resected tissue will be immediately homogenized by grinding, and the tissue homogenate will then be analyzed using this detection system to determine its histological characteristics. Pathological confirmation will further validate the method. This approach aims to improve the accuracy and efficiency of intraoperative assessment of breast-conserving surgical margins and SLN status, thereby effectively reducing local recurrence rates and complications.",[249,250,31,251],"Sentinel Lymph Node","Breast Cancers","Margin Assessment",[249,253,254,255,256],"Surface Enhanced Raman Spectroscopy","EpCAM","Breast cancers","Surgical margin","2025-06-04",{"date":259,"type":42},"2025-06-12",{"date":261,"type":21},"2025-06-15",{"date":263,"type":21},"2026-07-01",{"name":265,"class":49},"Yunnan Cancer Hospital",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":72},"100588122","sabr-primer---evaluating-stereotactic-ablative-radiotherapy-for-primary-and-regional-breast-tumors-100588122","NCT06937281","SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors","A Phase II Trial Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors (SABR-PRIMeR)","SABR PRIMER","Inclusion Criteria:\n\n1. Pathologically confirmed AJCC 7th\u002F8th edition Stage IV invasive ductal carcinoma or invasive lobular carcinoma of the breast.\n2. Measurable disease in the breast, suitable to receive radiotherapy.\n3. Receiving or planned to receive systemic therapy.\n\n   a. The following should be held for the duration of treatment: cytotoxic chemotherapy, CDK4\u002F6 inhibitors, T-DXd\n4. Patients are allowed to have SABR for oligometastatic disease as clinically indicated\n5. Age 18 or older\n6. ECOG Performance Status 0-2\n7. Life expectancy greater than 6 months\n8. Able and willing to provide informed consent\n9. Able to complete patient reported outcome questionnaires\n\nExclusion Criteria:\n\n1. Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia, pregnancy\n2. Previous history of locoregional radiotherapy to the ipsilateral breast",{"count":245,"type":21},[172],"The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer.\n\nSecondary objectives will be overall survival, progression-free survival and time to switch of next line of systemic therapy.\n\nRadiation-related adverse events will be assess, with a specific focus on dermatitis, lymphedema and brachial plexopathy.\n\nThe exploratory objective is to correlate toxicities and outcomes with peripheral blood biomarkers and circulating tumor DNA to potentially help predict responses in future patients receiving combined therapy.",[278,31],"Breast Cancer",[280],"SABR","2025-04-22",{"date":283,"type":42},"2025-04-24",{"date":285,"type":21},"2025-07-01",{"date":287,"type":21},"2030-07-30",{"name":237,"class":49},{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":168,"minAge":18,"maxAge":136,"enrollmentInfo":296,"targetDuration":4,"studyType":246,"phases":4,"briefSummary":297,"conditions":298,"keywords":299,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":72},"100570893","tumor-targeted-nir-ii-fluorescent-molecular-probes-for-the-identification-of-breast-cancer-tissue-and-sln-metastatic-status-100570893","NCT06713161","Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status","NIR-II","Inclusion Criteria:\n\n* Adult patients between 18-75 years of age\n* Female\n* Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment\n* Good operative candidate\n* Subject capable of giving informed consent and participating in the process of consent\n\nExclusion Criteria:\n\n* Patients unable to participate in the consent process\n* Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc\n* Other conditions that the researcher considers inappropriate to participate in the study",{"count":245,"type":21},"Accurate evaluation of tumor boundaries in breast-conserving surgery is closely associated with reducing the second operation of patients. Meanwhile, accurately assessing sentinel lymph node (SLN) metastasis is crucial for determining the extent of axillary lymph node dissection (ALND) and minimizing complications. Near-infrared-II (NIR-II) fluorescence imaging using molecular agents has shown promise for in situ imaging during resection. However, very effective probes can be applied to clinical trials up to now, which limits the clinical application of fluorescence imaging. Here we developed a new technology that can quickly differentiation between cancer and para-cancer tissue as well as metastatic and normal sentinel lymph nodes(SLN). In brief, the fresh tissues were incubated with the probe immediately after intraoperative resection and imaged to identify the tumor area and distinguish the metastatic status of SLN. The accuracy of fluorescence imaging was confirmed by pathological diagnosis.",[278,249,31,251],[294,278,249,300,31],"Surgical Navigation","2024-11-27",{"date":303,"type":42},"2024-12-03",{"date":305,"type":42},"2024-09-01",{"date":307,"type":21},"2025-12-25",{"name":265,"class":49},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":326,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":338,"leadSponsor":340,"locationsCount":342},"100543508","longitudinal-study-of-local-ablative-therapy-in-oligometastatic-disease-100543508","NCT06356779","Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease","A National Longitudinal Study of Metastases-directed Local Ablative Therapy for Patients With Oligometastatic Disease - a Combined Interventional and Observational Trial","OLIGO-DK","Inclusion Criteria:\n\n* Histology or cytology proven non-haematological cancer\n* Stage IV disease\n* ECOG performance status ≤ 2\n* Life expectancy \\> 6 months\n* A baseline scan within 42 days of inclusion (PET-CT or CT or MRI scan) is required, preferably within 28 days for optimal prospective evaluation\n* Primary tumor must be controlled, defined by the radiographical response of the primary tumor by systemic or local treatment. If progressing, it is planned to be treated with local ablative therapy (LAT)\n* Oligometastatic disease according to the ESTRO-EORTC classification, both de-novo and induced, including oligoprogression\n* A maximum of five oligometastases or oligopersistent\u002Foligoprogressive lesions. More than five metastases are allowed in the following cases, 1) location in a defined anatomical entity or 2) location in immediate proximity and as such, cannot be treated separately\n* All oligometastatic lesions must be planned for definitive LAT. If all visible\u002Fprogressive\u002Fpersistent disease is not treated, the patient cannot be included\n* Local ablative therapy must be deemed clinically relevant for the individual patient by the treating team of physicians, or a multidisciplinary team and discussion must be documented in the patient chart\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Pregnancy\n* Diffuse cancer disease, which cannot be locally ablated, i.e., leptomeningeal carcinomatosis, malignant pleural effusions, lymphangitic carcinomatosis, or peritoneal carcinomatosis\n* If LAT is deemed unsafe by the MDT (e.g., tumor perforation of hollow organs)\n\nIn addition, the patients receiving SBRT to oligometastatic sites should comply with the following criteria.\n\n* The size of the target is limited by the ability to safely deliver locally ablative doses to the metastatic lesions. Generally, an upper limit of 5 cm is recommended\n* If the patient has received previous radiotherapy, the combined dose at the radiation site must not exceed the dose constraints according to Appendix 2 - Radiotherapy Recommendations",{"count":318,"type":21},1200,[172],"This prospective national multicenter observational and interventional study aims to assess the longitudinal disease trajectory of patients with oligometastatic disease (OMD) who receive local metastasis-directed therapy. Patients with any category of OMD from any non-hematological cancer are eligible for inclusion. Local ablative therapy (LAT) includes surgical metastasectomy, radiotherapy, thermal ablation, and electroporations.\n\nThe primary objective is to assess the time to failure of LAT strategy in patients with OMD from any primary cancer treated with all LAT modalities.",[322,31,323,324,325,150],"Oligometastatic Disease","Ablation Techniques","Radiotherapy","Stereotactic Radiation",[327,328,329,330,331,332,333],"oligometastatic disease","metastases-directed therapy","metastasectomy","thermal ablation","stereotactic ablative radiotherapy","stereotactic radiosurgery","endpoints","2024-04-15",{"date":336,"type":42},"2024-04-16",{"date":334,"type":42},{"date":339,"type":21},"2035-12-31",{"name":341,"class":49},"Gitte Fredberg Persson MD PhD",11]